- Home
- ATNI vs YMAB Comparison
ATNI vs YMAB Comparison
Compare ATNI & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNI
- YMAB
- Stock Information
- Founded
- ATNI 1987
- YMAB 2015
- Country
- ATNI United States
- YMAB United States
- Employees
- ATNI N/A
- YMAB N/A
- Industry
- ATNI Telecommunications Equipment
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ATNI Telecommunications
- YMAB Health Care
- Exchange
- ATNI Nasdaq
- YMAB Nasdaq
- Market Cap
- ATNI 328.8M
- YMAB 270.5M
- IPO Year
- ATNI 1991
- YMAB 2018
- Fundamental
- Price
- ATNI $20.27
- YMAB $4.50
- Analyst Decision
- ATNI Strong Buy
- YMAB Buy
- Analyst Count
- ATNI 2
- YMAB 11
- Target Price
- ATNI $31.00
- YMAB $18.73
- AVG Volume (30 Days)
- ATNI 93.2K
- YMAB 322.9K
- Earning Date
- ATNI 03-04-2025
- YMAB 03-04-2025
- Dividend Yield
- ATNI 4.73%
- YMAB N/A
- EPS Growth
- ATNI N/A
- YMAB N/A
- EPS
- ATNI N/A
- YMAB N/A
- Revenue
- ATNI $729,075,000.00
- YMAB $87,685,000.00
- Revenue This Year
- ATNI $3.02
- YMAB $20.07
- Revenue Next Year
- ATNI $0.27
- YMAB $8.76
- P/E Ratio
- ATNI N/A
- YMAB N/A
- Revenue Growth
- ATNI N/A
- YMAB 3.38
- 52 Week Low
- ATNI $14.74
- YMAB $4.25
- 52 Week High
- ATNI $33.72
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- ATNI 49.75
- YMAB 36.51
- Support Level
- ATNI $20.94
- YMAB $4.65
- Resistance Level
- ATNI $22.23
- YMAB $5.25
- Average True Range (ATR)
- ATNI 1.14
- YMAB 0.30
- MACD
- ATNI -0.31
- YMAB 0.02
- Stochastic Oscillator
- ATNI 9.02
- YMAB 21.92
About ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.